Your browser doesn't support javascript.
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.
Peluso, Michael J; Takahashi, Saki; Hakim, Jill; Kelly, J Daniel; Torres, Leonel; Iyer, Nikita S; Turcios, Keirstinne; Janson, Owen; Munter, Sadie E; Thanh, Cassandra; Donatelli, Joanna; Nixon, Christopher C; Hoh, Rebecca; Tai, Viva; Fehrman, Emily A; Hernandez, Yanel; Spinelli, Matthew A; Gandhi, Monica; Palafox, Mary-Ann; Vallari, Ana; Rodgers, Mary A; Prostko, John; Hackett, John; Trinh, Lan; Wrin, Terri; Petropoulos, Christos J; Chiu, Charles Y; Norris, Philip J; DiGermanio, Clara; Stone, Mars; Busch, Michael P; Elledge, Susanna K; Zhou, Xin X; Wells, James A; Shu, Albert; Kurtz, Theodore W; Pak, John E; Wu, Wesley; Burbelo, Peter D; Cohen, Jeffrey I; Rutishauser, Rachel L; Martin, Jeffrey N; Deeks, Steven G; Henrich, Timothy J; Rodriguez-Barraquer, Isabel; Greenhouse, Bryan.
  • Peluso MJ; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA. michael.peluso@ucsf.edu.
  • Takahashi S; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Hakim J; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Kelly JD; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
  • Torres L; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Iyer NS; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Turcios K; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Janson O; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Munter SE; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Thanh C; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Donatelli J; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Nixon CC; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Hoh R; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Tai V; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Fehrman EA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Hernandez Y; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Spinelli MA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Gandhi M; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Palafox MA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Vallari A; Abbott Laboratories, Abbott Park, IL, USA.
  • Rodgers MA; Abbott Laboratories, Abbott Park, IL, USA.
  • Prostko J; Abbott Laboratories, Abbott Park, IL, USA.
  • Hackett J; Abbott Laboratories, Abbott Park, IL, USA.
  • Trinh L; Abbott Laboratories, Abbott Park, IL, USA.
  • Wrin T; Monogram Biosciences Inc., South San Francisco, CA, USA.
  • Petropoulos CJ; Monogram Biosciences Inc., South San Francisco, CA, USA.
  • Chiu CY; Monogram Biosciences Inc., South San Francisco, CA, USA.
  • Norris PJ; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • DiGermanio C; Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, USA.
  • Stone M; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Busch MP; Vitalant Research Institute, San Francisco, CA, USA.
  • Elledge SK; Vitalant Research Institute, San Francisco, CA, USA.
  • Zhou XX; Vitalant Research Institute, San Francisco, CA, USA.
  • Wells JA; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Shu A; Vitalant Research Institute, San Francisco, CA, USA.
  • Kurtz TW; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Pak JE; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Wu W; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Burbelo PD; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
  • Cohen JI; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Rutishauser RL; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Martin JN; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Deeks SG; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Henrich TJ; National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.
  • Rodriguez-Barraquer I; Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Greenhouse B; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
Sci Adv ; 7(31)2021 Jul.
Article in English | MEDLINE | ID: covidwho-1334521
ABSTRACT
Interpretation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveillance studies is limited by poorly defined performance of antibody assays over time in individuals with different clinical presentations. We measured antibody responses in plasma samples from 128 individuals over 160 days using 14 assays. We found a consistent and strong effect of disease severity on antibody magnitude, driven by fever, cough, hospitalization, and oxygen requirement. Responses to spike protein versus nucleocapsid had consistently higher correlation with neutralization. Assays varied substantially in sensitivity during early convalescence and time to seroreversion. Variability was dramatic for individuals with mild infection, who had consistently lower antibody titers, with sensitivities at 6 months ranging from 33 to 98% for commercial assays. Thus, the ability to detect previous infection by SARS-CoV-2 is highly dependent on infection severity, timing, and the assay used. These findings have important implications for the design and interpretation of SARS-CoV-2 serosurveillance studies.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abh3409

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abh3409